Furthermore, these tyrosine kinase inhibitors are believed to work because they primarily inhibit the Vascular Endothelial Growth Factor (VEGF) receptor present on non-cancerous endothelial cells1, and therefore reversal of gene expression on the ccRCC cells is not expected to occur. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.